Skip to main content
Log in

Inhaled Mometasone Furoate

A Review of its Use in Adults and Adolescents with Persistent Asthma

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Mometasone furoate is a corticosteroid with relatively high in vitro potency. Recent randomised, double-blind, multicentre trials have assessed the efficacy of mometasone furoate delivered by dry powder inhaler over 12 weeks in adults and adolescents with mild to severe persistent asthma.

Mometasone furoate 200µg twice daily or 400µg once daily in the morning or 200µg once daily in the evening improved lung function, asthma symptom scores and use of rescue medication to a significantly greater extent than placebo in patients who had previously received only short-acting inhaled β2-adrenoceptor agonists alone as treatment in 3 trials (n = 195 to 306). In studies in 227 to 733 patients with mild to moderate asthma who were receiving ongoing treatment with inhaled corticosteroids prior to enrolment, mometasone furoate 100 to 400µg twice daily was consistently better at improving the above indicators of asthma than placebo. Mometasone furoate 100 to 200µg twice daily was as effective as beclomethasone dipropionate 200µg twice daily or budesonide 400µg twice daily and mometasone furoate 200µg twice daily was as effective as fluticasone propionate 250µg twice daily.

Mometasone furoate 400 or 800µg twice daily was also consistently more effective than placebo in reducing oral corticosteroid dosages and improving lung function and asthma symptoms in 132 patients with oral corticosteroid-dependent asthma. Once daily administration of mometasone furoate 400µg appears to be as effective at improving indicators of asthma as twice daily administration of 200µg.

Patients receiving mometasone furoate ≤800 µg/day and recipients of placebo experienced a similar overall incidence of adverse events considered to be related to treatment. The most common of these events were oral candidiasis, headache, pharyngitis and dysphonia. Mometasone furoate 100 to 400µg twice daily, beclomethasone dipropionate 200µg twice daily, budesonide 400µg twice daily or fluticasone propionate 250µg twice daily were similarly tolerated.

Conclusion: Inhaled mometasone furoate is well tolerated, with minimal systemic activity and is equally effective when administered as a divided dose or as a single daily dose. Use of the drug can result in a decrease in requirements for oral corticosteroids in patients with oral corticosteroid-dependent asthma and is as effective as other inhaled corticosteroids currently used in the treatment of mild to moderate persistent asthma. Thus mometasone furoate is suitable for the control of mild to severe persistent asthma in adults or adolescents.

Pharmacodynamic Properties

Mometasone furoate binds to the corticosteroid receptor with greater affinity than fluticasone propionate, budesonide, triamcinolone acetonide and dexamethasone. Studies of cells derived from humans show that mometasone furoate is similar in in vitro anti-inflammatory potency to fluticasone propionate and more potent than budesonide, beclomethasone dipropionate and triamcinolone acetonide. In patients with mild to moderate persistent asthma, treatment with mometasone furoate 50 or 100µg delivered by dry powder inhaler (DPI) twice daily significantly reduced bronchial hyper-responsiveness induced by adenosine monophosphate or an allergen.

Mometasone furoate ≤1200 µg/day has a minimal effect on HPA axis function in patients with mild to moderate asthma as measured by the mean serum cortisol area under the plasma concentration-time curve determined over 24 hours (AUC24). All patients receiving mometasone furoate or placebo in 3 randomised, evaluator-blind, placebo-controlled trials had a normal response to an injection of tetracosactide 0.25mg. Mometasone furoate ≤1600 µg/day produced less reduction in serum cortisol AUC24 than prednisone 10 mg/day or fluticasone propionate 880µg daily (delivered dose). Administration of mometasone furoate by DPI may lower serum cortisol AUC24 to a greater extent than administration by metered dose inhaler (MDI), although no direct comparisons have been carried out.

Pharmacokinetic Properties

Very little mometasone furoate is absorbed systemically after it has been inhaled in healthy volunteers. The mean bioavailability of a single dose of mometasone furoate 400µg (delivered by DPI) is <1%. Mean plasma concentrations after this dose are below the lower limit of quantification (0.05 µg/L), the mean area under the plasma concentration-time curve from Oh to the final measurable sampling time is 0.09 µg/L · h and the peak plasma concentration is 0.05 µg/L. Systemic exposure to the drug after multiple dose administration of mometasone furoate 200 to 800 µg/day by DPI (as measured by plasma mometasone furoate concentrations) is also minimal. Most inhaled mometasone furoate is swallowed and excreted unabsorbed and unchanged in faeces. Any drug that is absorbed appears to be extensively metabolised by cytochrome P450 3A4 in the liver and excreted in the urine and/or bile. The systemic clearance of mometasone furoate 400µg after intravenous administration is 53.5 L/h, which is similar to that of other inhaled corticosteroids.

Therapeutic Efficacy

In patients with mild to moderate persistent asthma who had previously been using short-acting inhaled β2-adrenoceptor agonists alone, mometasone furoate 200µg twice daily, 400µg once daily in the morning or 200µg once daily in the evening for 12 weeks produced significantly greater improvements in forced expiratory volume in 1 second (FEV1), morning peak expiratory flow rate (PEF), asthma symptom scores and use of rescue medication than placebo in 3 randomised, double-blind, multicentre trials (n = 195 to 306). Significant improvements in some parameters were seen as early as 24 hours after initiation of mometasone furoate 400µg once daily in the morning.

Mometasone furoate 100 to 400µg twice daily consistently improved FEV1, PEF, symptom scores and rescue medication use to a significantly greater extent than placebo in randomised, double-blind, multicentre studies (n = 227 to 365) in patients with mild to moderate asthma who had received inhaled corticosteroids before study enrolment. In a similar patient group, mometasone furoate 200 or 400µg twice daily was significantly more effective than budesonide 400µg twice daily in improving some indicators of asthma in a randomised, evaluator-blind, multicentre trial (n = 731) and mometasone furoate 100 and 200µg twice daily was generally as effective as beclomethasone dipropionate 200µg twice daily in a well designed study (n = 365). Mometasone furoate 200µg twice daily was as effective as fluticasone propionate 250µg twice daily in a randomised, evaluator-blind study (n = 733).

In another well designed, 12-week study (n = 132) conducted in adults and adolescents with moderate to severe persistent asthma dependent on oral corticosteroid treatment, mometasone furoate 400 or 800µg twice daily was consistently more effective than placebo in reducing oral prednisone dosages and improving lung function and asthma symptoms. Further reductions in oral corti-costeroid dosages were observed for the duration of a 9-month, noncomparative extension of this study where all patients were initially switched to mometasone furoate 800µg twice daily.

Administering mometasone furoate 400µg once daily in the morning is generally as effective at improving indicators of asthma as administering 200µg of the drug twice daily in patients with mild to moderate persistent asthma who had previously received short-acting inhaled β2-adrenoceptor agonists or inhaled corticosteroid therapy. Evening administration of once daily mometasone furoate 200µg appears to be more effective than administration of this dosage in the morning.

Tolerability

Mometasone furoate delivered by DPI is well tolerated: the overall incidence of treatment-related adverse events was generally similar in patients receiving mometasone furoate ≤800 µg/day (18 to 28%) and patients receiving placebo (19 to 22%) in 3 well designed studies. Mometasone furoate 200µg twice daily or 400µg once daily produced the same incidence of adverse events. Patients receiving mometasone furoate ≤800 µg/day for 12 weeks most commonly experienced oral candidiasis (1 to 15%), headache (2 to 11%), pharyngitis (1 to 10%) and dysphonia (1 to 5%). Fewer than 3% of mometasone furoate or placebo recipients withdrew from studies because of an adverse event possibly or probably related to treatment. The overall incidence of adverse events related to treatment was similar with mometasone furoate 100 to 400µg twice daily and beclomethasone dipropionate 200µg twice daily, budesonide 400µg twice daily or fluticasone propionate 250µg twice daily in comparative trials. Mometasone furoate ≤1600 µg/day is well tolerated for up to 1 year of treatment according to a noncomparative study.

Dosage and Administration

Mometasone furoate administered by Twisthaler™ DPI is recommended for the prophylactic management of mild to severe asthma in adults and adolescents ≥12 years.

Mometasone furoate 400µg once daily (metered dose) is the recommended starting dosage in patients previously maintained on bronchodilators alone or inhaled corticosteroids. Some patients may maintain better control if they receive mometasone furoate in divided doses (200µg twice daily). The drug should be titrated to the lowest dose at which effective control of asthma is maintained.

Patients with severe asthma receiving systemic corticosteroids can initially receive mometasone furoate at a dosage of 400µg twice daily (the maximum recommended dose). At intervals of 1 to 2 weeks, the systemic corticosteroid can then be slowly withdrawn by no more than 2.5 mg/day of prednisone (or equivalent) at a time, in conjunction with patient monitoring. Once reduction of systemic corticosteroid is complete, mometasone furoate can be titrated to the lowest effective dose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Fig. 2
Table III
Table IV
Fig. 3
Fig. 4
Table V
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. National Heart, Lung, and Blood Institute Information Center., Bethesda, 1997 Feb

  2. National Heart Lung and Blood Institute. Global strategy for asthma management and prevention. NHLBI/WHO workshop report. National Institutes of Health. 1995 Jan; Publication Number 95-3659

  3. Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998; 102(4): 531–8

    Article  PubMed  CAS  Google Scholar 

  4. Lemanske RF. Inflammatory events in asthma: an expanding equation. J Allergy Clin Immunol 2000 Jun; 105: S633–6

    Article  PubMed  CAS  Google Scholar 

  5. Bousquet J, Jeffery PK, Busse WW, et al. Asthma: from bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720–45

    PubMed  CAS  Google Scholar 

  6. Barnes PJ. Mechanisms of action of glucocorticoids in asthma. Am J Respir Crit Care Med 1996; 154 Suppl.: S21–7

    PubMed  CAS  Google Scholar 

  7. Cave A, Arlett P, Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol Ther 1999; 83(3): 153–79

    Article  PubMed  CAS  Google Scholar 

  8. Prakash A, Benfield P. Topical mometasone: a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs 1998 Jan; 55(1): 145–63

    Article  PubMed  CAS  Google Scholar 

  9. Onrust SV, Lamb HM. Mometasone furoate: a review of its intranasal use in allergic rhinitis. Drugs 1998 Oct; 56: 725–45

    Article  PubMed  CAS  Google Scholar 

  10. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. Am J Respir Crit Care Med 1998; 157: S1–S53

    PubMed  CAS  Google Scholar 

  11. Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittel Forschung 1998; 48: 956–60

    PubMed  CAS  Google Scholar 

  12. Crocker IC, Church MK, Newton S, et al. Glucocorticoids inhibit proliferation and interleukin-4 and interleukin-5 secretion by aeroallergen-specific T-helper type 2 cell lines. Ann Allergy Asthma Immunol 1998; 80: 509–16

    Article  PubMed  CAS  Google Scholar 

  13. Umland SP, Nahrebne K, Razac S, et al. The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-γ production by cultured primary CD4+ T cells. J Allergy Clin Immunol 1997; 100: 511–9

    Article  PubMed  CAS  Google Scholar 

  14. Stellato C, Atsuta J, Bickel CA, et al. An in vitro comparison of commonly used topical glucocorticoid preparations. J Allergy Clin Immunol 1999; 104(3): 623–9

    Article  PubMed  CAS  Google Scholar 

  15. Crocker IC, Chang Y-Z, Bewtra AK, et al. Glucocorticosteroids inhibit leukotriene production. Ann Allergy Asthma Immunol 1997; 78(5): 497–505

    Article  PubMed  CAS  Google Scholar 

  16. Papi A, Papadopoulos NG, Degitz K, et al. Corticosteroids inhibit rhinovirus-induced intercellular adhesion molecule-1 up-regulation and promoter activation on respiratory epithelial cells. J Allergy Clin Immunol 2000; 105(2) I: 318–26

    Article  PubMed  CAS  Google Scholar 

  17. Barton BE, Jakway JP, Smith SR, et al. Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol Immunotoxicol 1991; 13(3): 251–61

    Article  PubMed  CAS  Google Scholar 

  18. Chapman RW, Sehring SJ, Garlisi CG, et al. Anti-inflammatory activity of inhaled mometasone furoate in allergic mice. Arzneimittel Forschung 1998; 48: 384–91

    PubMed  CAS  Google Scholar 

  19. Inman MD, Watson RM, Rerecich T, et al. Effect of low doses of mometasone furoate (MF) dry powder inhaler (DPI) on allergen-induced asthmatic responses [abstract]. Am J Respir Crit Care Med 2000 Mar; 161 (3) Suppl.: A187

    Google Scholar 

  20. Holgate ST, Arshad H, Stryszak P, et al. Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma. J Allergy Clin Immunol 2000 May; 105: 906–11

    Article  PubMed  CAS  Google Scholar 

  21. Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997; 52: 476–82

    Article  PubMed  CAS  Google Scholar 

  22. Affrime MB, Kosoglou T, Thonoor CM, et al. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 2000; 118: 1538–46

    Article  PubMed  CAS  Google Scholar 

  23. Bernstein DI, Berkowitz RB, Chervinsky P, et al. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999 Sep; 93: 603–12

    Article  PubMed  CAS  Google Scholar 

  24. Murray JJ, Busse W, Dockhorn R, et al. Long-term safety of mometasone furoate (MF) administered by dry powder inhaler (DPI) in patients with moderate persistent asthma [abstract no. P1997]. Eur Respir J Suppl 2000; 16 Suppl. 31: 280s–1s

    Google Scholar 

  25. Noonan M, Karpel JP, Bensch GW, et al. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol 2001; 86: 36–43

    Article  PubMed  CAS  Google Scholar 

  26. Bousquet J, D’Urzo A, Hebert J, et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J 2000 Nov; 16(5): 808–16

    Article  PubMed  CAS  Google Scholar 

  27. Glaxo Wellcome Inc. Fluticasone propionate prescribing information. Research Triangle Park, North Carolina, U.S.A., 1999

  28. Vargas R, Dockhorn RJ, Findlay SR, et al. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol 1998; 102: 191–7

    Article  PubMed  CAS  Google Scholar 

  29. Affrime MB, Cuss F, Padhi D, et al. Bioavailability and metabolism of mometasone fuorate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000; 40: 1227–36

    PubMed  CAS  Google Scholar 

  30. Affrime MB, Kosoglou T. The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild to moderate persistent asthma [abstract no. 346]. J Allergy Clin Immunol 2001 Feb; 107(2): S104

    Google Scholar 

  31. Pickering H, Pitcairn GR, Hirst PH, et al. Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler. Clin Ther 2000; 22(12): 1483–93

    Article  PubMed  CAS  Google Scholar 

  32. Affrime MB, Cayen M, Kosoglou T, et al. The pharmacokinetics of mometasone furoate administered by dry powder inhaler in patients with chronic liver disease [abstract no. P37]. Ann Allergy Asthma Immunol 2001 Jan; 86(1): 103

    Google Scholar 

  33. Schering Corporation. Mometasone furoate monohydrate nasal spray prescribing information. Kenilworth, New Jersey, U.S.A., 1999

  34. Bensch GW, Nayak AS, Schenkel E, et al. Once-daily, evening dosing with mometasone furoate (MF) improves pulmonary function in patients with mild to moderate asthma [abstract]. Am J Respir Crit Care Med 2000 Mar; 161 Suppl.: A187

    Google Scholar 

  35. Kemp JP, Berkowitz RB, Miller D, et al. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 2000 Sep; 106: 485–92

    Article  PubMed  CAS  Google Scholar 

  36. Nayak AS, Banov C, Corren J, et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol 2000 Apr; 84: 417–24

    Article  PubMed  CAS  Google Scholar 

  37. Nathan RA, Nayak AS, Graft DF, et al. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol 2001; 86: 203–10

    Article  PubMed  CAS  Google Scholar 

  38. O’Connor B, Bonnaud G, Haahtela T, et al. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol 2001 Apr; 86(4): 397–404

    Article  PubMed  Google Scholar 

  39. Corren J, Berkowitz RB, Murray JJ, et al. Mometasone furoate 400 mcg once daily is more effective than budesonide 400 mcg once daily in improving pulmonary function in patients with moderate persistent asthma [abstract]. Am J Respir Crit Care Med 2001; 163(5): A587

    Google Scholar 

  40. Fish JE, Karpel JP, Craig TJ, et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 2000 Nov; 106: 852–60

    Article  PubMed  CAS  Google Scholar 

  41. Hebert JR, Kunkel G, Neffen H, et al. The safety and efficacy of mometasone furoate administered by dry powder inhaler in patients previously maintained on high doses of prescribed inhaled corticosteroids [abstract no. 36]. J Allergy Clin Immunol 2000 Jan; 105 Pt 2: S12

    Article  Google Scholar 

  42. Hebert JR, Kunkel G, Neffen H, et al. Mometasone furoate therapy improves asthma symptoms in addition to pulmonary function in patients previously maintained on high doses of inhaled corticosteroids (ICS) [abstract]. Am J Respir Crit Care Med 2000 Mar; 161(3) Suppl. Pt 2: A187

    Google Scholar 

  43. Schenkel E, Miller D, Angelini B, et al. Clinical assessment of inspiratory airflow profiles with the new mometasone furoate dry powder inhaler (MF-DPI) [abstract]. Ann Allergy Asthma Immunol 2000 Jan; 84: 158

    Google Scholar 

  44. Kenyon D, Yang TT, Ambrosio T. Retention of dose uniformity with the new mometasone furoate dry powder inhaler (MF-DPI) [abstract no. 43]. J Allergy Clin Immunol 2000; 105 (1) Pt 2: S14–5

    Article  Google Scholar 

  45. Li S, Yang TT, Wyka B, et al. Dose delivery and dose uniformity of the mometasone furoate dry powder inhaler at different flow rates [abstract no. 334]. J Allergy Clin Immunol 2001 Feb; 107(2): S100

    Google Scholar 

  46. Karpel JP. An easy-to-use dry-powder inhaler. Adv Ther 2000 Nov/Dec; 17(6): 282–6

    Article  PubMed  CAS  Google Scholar 

  47. Nayak AS, Lampl KL, Segall N, et al. Long term use of once-daily mometasone furoate is effective and well tolerated in patients with mild to moderate persistent asthma [abstract no. 328]. J Allergy Clin Immunol 2001 Feb; 107 Suppl.: S98

    Google Scholar 

  48. Kemp JP, Nayak AS, Berkowitz RB, et al. Rapid onset of action of mometasone furoate (MF) administered once daily by dry powder inhaler (DPI) [abstract no. P2375]. Eur Respir J Suppl 2000 Aug; 16 Suppl. 31: 338s

    Google Scholar 

  49. Karpel JP, Fish JE, Craig TJ, et al. Mometasone furoate administered by metered dose inhaler reduces oral prednisone requirements and improves pulmonary function of patients with severe persistent asthma [abstract]. Eur Respir J Suppl 2000 Aug; 16 Suppl. 31: 93s–4s

    Google Scholar 

  50. Schering-Plough Ltd. Mometasone furoate (Asmanex) prescribing information. Hertfordshire, UK, Jan. 2001

  51. British Thoracic Society. The British guidelines on asthma management 1995 review and position statement. Thorax 1997 Feb; 52 Suppl. 1: S1–S21

    Article  Google Scholar 

  52. Weltman JK. The use of inhaled corticosteroids in asthma. Allergy Asthma Proc 1999 Jul–Aug; 20: 255–60

    Article  PubMed  CAS  Google Scholar 

  53. Jarvis B, Faulds D. Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages ≤500 µg/day in adults and adolescents with mild to moderate asthma. Drugs 1999 May; 57(5): 769–803

    Article  PubMed  CAS  Google Scholar 

  54. Hvizdos KM, Jarvis B. Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs 2000 Nov; 60(5): 1141–78

    Article  PubMed  CAS  Google Scholar 

  55. Haahtela T, Järvinen M, Kava T, et al. Comparison of a β2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388–92

    Article  PubMed  CAS  Google Scholar 

  56. Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990; 142: 832–6

    PubMed  CAS  Google Scholar 

  57. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a βi-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90: 32–42

    Article  PubMed  CAS  Google Scholar 

  58. Bleeker ER, Welch MJ, Weinstein SF, et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000; 105: 1123–9

    Article  Google Scholar 

  59. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Ann Intern Med 1999; 130: 487–95

    PubMed  CAS  Google Scholar 

  60. Price JF, Russell G, Hindmarsh PC, et al. Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma. Pediatr Pulmonol 1997 Sep; 24(3): 178–86

    Article  PubMed  CAS  Google Scholar 

  61. Price JF, Weiler PH. Comparison of fluticasone propionate and sodium cromoglycate for the treatment of childhood asthma (an open parallel group study). Respir Med 1995 May; 89(5): 363–8

    Article  PubMed  CAS  Google Scholar 

  62. Lipworth BJ. Modern drug treatment of chronic asthma. BMJ 1999 Feb 6; 318: 380–4

    Article  PubMed  CAS  Google Scholar 

  63. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf 2000 Jul;23: 11–33

    Article  PubMed  CAS  Google Scholar 

  64. Wilson AM, Clark DJ, McFarlane L, et al. Adrenal suppression with high doses of inhaled fluticasone propionate and triamcinolone acetonide in healthy volunteers. Eur J Clin Pharmacol 1997; 53: 33–7

    Article  PubMed  CAS  Google Scholar 

  65. Donahue JG, Fuhlbrigge AL, Finkelstein JA, et al. Asthma pharmacotherapy and utilization by children in 3 managed care organizations. J Allergy Clin Immunol 2000; 106: 1108–14

    Article  PubMed  CAS  Google Scholar 

  66. Legorreta AP, Christian-Herman J, O’Connor RD, et al. Comparison with national asthma management guidelines and specialty care: a health maintenance organization experience. Arch Intern Med 1998 Mar 9; 158: 457–64

    Article  PubMed  CAS  Google Scholar 

  67. Jatulis DE, Meng Y-Y, Elashoff RM, et al. Preventive pharmacologic therapy among asthmatics: five years after publication of guidelines. Ann Allergy Asthma Immunol 1998; 81: 82–8

    Article  PubMed  CAS  Google Scholar 

  68. Lang DM, Sherman MS, Polansky M, et al. Guidelines and realities of asthma management: the Philadelphia story. Arch Intern Med 1997; 157: 1193–200

    Article  PubMed  CAS  Google Scholar 

  69. Gaist D, Hallas J, Hansen NG, et al. Are young adults with asthma treated sufficiently with inhaled steroids? A population-based study of prescription data from 1991 and 1994. Br J Clin Pharmacol 1996; 41: 285–9

    Article  PubMed  CAS  Google Scholar 

  70. Ferrante E, Muzzolon R, Fuso L, et al. Bronchial asthma: still an inadequately assessed and improperly treated disease. J Asthma 1994; 31(2): 117–21

    Article  PubMed  CAS  Google Scholar 

  71. Bousquet J, Knani J, Henry C, et al. Undertreatment in a non-selected population of adult patients with asthma. J Allergy Clin Immunol 1996; 98: 514–21

    Article  PubMed  CAS  Google Scholar 

  72. Kaur B, Anderson HR, Austin J, et al. Prevalence of asthma symptoms, diagnosis, and treatment in 12–14 year old children across Great Britain (international study of asthma and allergies in childhood, ISAAC UK). BMJ 1998 Jan 10; 316: 118–24

    Article  PubMed  CAS  Google Scholar 

  73. Biais R, Grégoire J-P, Rouleau R, et al. Ambulatory use of inhaled β2-agonists for the treatment of asthma in Quebec: a population-based utilization review. Chest 2001; 119: 1316–21

    Article  Google Scholar 

  74. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332–6

    Article  PubMed  CAS  Google Scholar 

  75. Van Ganse E, Hubloue I, Vincken W, et al. Actual use of inhaled corticosteroids and risk of hospitalisation: a case-control study. Eur J Clin Pharmacol 1997; 51: 449–54

    Article  PubMed  Google Scholar 

  76. Donahue JG, Weiss ST, Livingston JM, et al. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997; 277(11): 887–91

    Article  PubMed  CAS  Google Scholar 

  77. Griffiths C, Naish J, Sturdy P, et al. Prescribing and hospital admissions for asthma in east London. BMJ 1996; 312: 481–2

    Article  PubMed  CAS  Google Scholar 

  78. Abramson MJ, Bailey MJ, Couper FJ, et al. Are asthma medications and management related to deaths from asthma? Am J Respir Crit Care Med 2001; 163: 12–8

    PubMed  CAS  Google Scholar 

  79. Markson LE, Vollmer WM, Fitterman L, et al. Insight into patient dissatisfaction with asthma treatment. Arch Intern Med 2001 Feb 12; 161:379–84

    Article  PubMed  CAS  Google Scholar 

  80. Campbell LM. Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment. Drugs 1999; 58 Suppl. 4: 25–33

    Article  PubMed  CAS  Google Scholar 

  81. Hyland ME. Rationale for once-daily therapy in asthma: compliance issues. Drugs 1999; 58 Suppl. 4: 1–6

    Article  PubMed  Google Scholar 

  82. Martin RJ, Banks-Schlegel S. Chronobiology of asthma. Am J Respir Crit Care Med 1998 Sep; 158(3): 1002–7

    PubMed  CAS  Google Scholar 

  83. Beam WR, Weiner DE, Martin RJ. Timing of prednisone and alterations of airways inflammation in nocturnal asthma. Am Rev Respir Dis 1992; 146: 1524–30

    PubMed  CAS  Google Scholar 

  84. Pincus DJ, Humeston TR, Martin RJ. Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 1997 Dec; 100(6): 771–4

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Miriam Sharpe.

Additional information

Various sections of the manuscript reviewed by: M. Campbell, Southbank Surgery, Glasgow, Scotland; S. Holt, Wellington Asthma Research Group, Wellington School of Medicine, Wellington, New Zealand; H.W. Kelly, Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA; M. Partridge, The Chest Clinic, Whipps Cross University Hospital, London, England; W.C. Tan, Department of Medicine, National University Hospital, Singapore

Sources: Medical literature published in any language since 1980 on mometasone, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International, Auckland, New Zealand). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: Medline search terms were (‘mometasone’ or ‘mometasone furoate’ or ‘SCH 32088’) and ‘asthma’. EMBASE search terms were (‘mometasone’ or ‘mometasone furoate’ or ‘momethasone furoate’ or ‘SCH 32088’) and ‘asthma’. AdisBase search terms were (‘mometasone’ or ‘mometasone furoate’ or ‘SCH-32088’) and ‘asthma’. Searches were last updated 19 June, 2001.

Selection: Studies in patients with persistent asthma who received mometasone. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Asthma, mometasone, pharmacodynamics, pharmacokinetics, therapeutic use.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharpe, M., Jarvis, B. Inhaled Mometasone Furoate. Drugs 61, 1325–1350 (2001). https://doi.org/10.2165/00003495-200161090-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161090-00011

Keywords

Navigation